Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 182 | 78 | 101 |
| Samples | 172 | 77 | 93 |
| Peptides | 80 | 17 | 66 |
Function
KRTAP5-2 · Keratin associated protein 5-2
Predicted to be located in cytosol. [provided by Alliance of Genome Resources, Apr 2022]
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 80 amino-acid changes on canonical ENST00000412090 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KRTAP5-2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KRTAP5-2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Mesothelioma | 4/62 6% | 2/165 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 7/1390 0% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Thyroid Gland Carcinoma | 3/45 7% | 13/1592 1% |
| Neuroendocrine Tumour | 7/154 5% | 0/577 0% |
| Melanoma | 8/210 4% | 11/1899 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Other Solid Cancers | 2/94 2% | 8/1515 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 3/810 0% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Colorectal Carcinoma | 4/143 3% | 13/3239 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Esophageal Carcinoma | 1/23 4% | 2/769 0% |
| Breast Carcinoma | 4/144 3% | 8/3264 0% |
| Endometrial Carcinoma | 1/42 2% | 1/612 0% |
| Head and Neck Carcinoma | 1/85 1% | 4/1574 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| Hepatocellular Carcinoma | 1/46 2% | 4/2210 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 3/2534 0% |
| Other Blood Cancers | 0/61 0% | 4/2725 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Other Sarcomas | 1/69 1% | 0/699 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 1/2550 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Bladder Carcinoma | 1/58 2% | 0/956 0% |
Mutation Distribution
Where KRTAP5-2 is mutated · all tissues, split by cell line vs tissue
How many mutations in KRTAP5-2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 182 mutations in KRTAP5-2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|